Avanir Pharmaceuticals
 Home  About  Investors  Product R&D  Employment  Contact

AVANIR PHARMACEUTICALS is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.

AVANIR'S products and product candidates address therapeutic markets that include central nervous system disorders, inflammation, and infectious disease.

Avanir Producs

Approved Products

product indicator abreva® (docosanol 10% cream)

Investigational Products

product indicator Zenvia™ for PBA
product indicator MIF Inhibitor
product indicator Zenvia™ for Diabetic Peripheral Neuropathic Pain
product indicator Selective Cytokine Inhibitor

product indicator Zenvia™ for Pseudobulbar Affect (PBA)
product indicator Zenvia™ for Diabetic Peripheral Neuropathic (DPN) Pain


Webcasts

2nd Quarter Fiscal Year 2008 Financial Results
Date: May 13, 2008
Begins: 11:00 a.m. ET

Latest News

May 13, 2008
AVANIR Reports Second Quarter Fiscal 2008 Financial Results

Apr 29, 2008
AVANIR Pharmaceuticals Invites Investors to Second Quarter Conference Call

Apr 21, 2008
AVANIR Regains Compliance with NASDAQ Listing Requirements

Home | About | Investors | Products | Employment | Contact
© 2002 Avanir Disclosure